Year: 2021

 Blagnac, France, November 03th 2021-5.35 pm, Montreal, Canada Turnover over the first 9 months as of September 30th 2021: -7.4% at €87.9M At constants exchange rate and perimeter *: -2.0% SOGECLAIR, designer and manufacturer of innovative high added-value solutions for mobility, announces today its turnover for the 3rd quarter 2021.At constants exchange rate and perimeter, the turnover for the 3rd quarter 2021 increases by 12.7% compared with the 3rd quarter 2020. Nine-month turnover decreases by 2% at constants exchange rates and perimeter.*Exchange rate variations over the period represent €1.6M, they were no significant in 2020.  Changes in the scope of consolidation over the period represent €-3.6M (restructuring in Germany).By division Turnover (€ million)9 months 2021 Turnover (€ million)9 months 2020   Variation as %     Aerospace ...

Uponor Corporation ANNOUNCEMENT 3.11.2021          Uponor Corporation: SHARE REPURCHASE 3.11.2021     In the Helsinki Stock Exchange         Trade date 3.11.2021  Bourse trade Buy  Share UPONOR  Amount 30,000 SharesAverage price/ share 20.4245 EURTotal cost 612,735.00 EUR          Uponor Corporation now holds a total of 222 206 sharesincluding the shares repurchased on 3.11.2021            On behalf of Uponor Corporation         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For more information, please contact:  Uponor Corporation    Susanna Inkinen    Vice President, Communications and Corporate ResponsibilityTel. +358 20 129 2081         www.uponorgroup.com       AttachmentUponor_3.11_trades ...

Suominen Corporation ANNOUNCEMENT 3.11.2021          Suominen Corporation: SHARE REPURCHASE 3.11.2021     In the Helsinki Stock Exchange         Trade date 3.11.2021  Bourse trade Buy  Share SUY1V  Amount 8,000 SharesAverage price/ share 4.9460 EURTotal cost 39,568.00 EUR          Suominen Corporation now holds a total of 642 661 sharesincluding the shares repurchased on 3.11.2021            On behalf of Suominen Corporation       Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For additional information, please contact:  Toni Tamminen, CFO, Suominen Corporation  tel. +358 (0)10 214 3051         www.suominen.fi    AttachmentSuominen 3.11 trades

Innofactor Plc ANNOUNCEMENT 3.11.2021          INNOFACTOR PLC: SHARE REPURCHASE 3.11.2021       In the Helsinki Stock Exchange         Trade date 3.11.2021  Bourse trade Buy  Share IFA1V  Amount 20,000 SharesAverage price/ share 1.5202 EURTotal cost 30,404.00 EUR          Innofactor Plc now holds a total of 160 000 sharesincluding the shares repurchased on 3.11.2021            On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_3.11_trades

Sunrise, FL, Nov. 03, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NextPlay Technologies, Inc. (NASDAQ: NXTP) (the “Company”), a digital business ecosystem for digital advertisers, consumers, video gamers and travelers, today announced the closing of its previously announced registered direct offering with certain institutional investors, pursuant to which the Company sold approximately $30 million worth of its common stock and warrants. Under the terms of the securities purchase agreement, the Company sold approximately 18.98 million shares of its common stock and warrants to purchase approximately 14.24 million shares of common stock. The warrants will be exercisable beginning May 1, 2022, have an exercise price of $1.97 per share, and will expire five years from the initial exercise date. The purchase price for one share...

Pascal Video ImageInvestmentPitch Media Video Discusses Pascal Biosciences and its Award of a National Cancer Institute Grant for its Acute Lymphoblastic Leukemia Program – Video Available on Investmentpitch.comVANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) — Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a biotechnology company targeting innovative therapies for serious diseases, including COVID-19, has been awarded a grant from the National Cancer Institute of the US National Institutes of Health. This two-year grant of US$343,750 will fund development of Pascal’s antibody drug for Acute Lymphoblastic Leukemia or “ALL”. For more information, please view the InvestmentPitch Media “video” which provides additional information about this news and the company, along with some comments...

Chicago, IL, Nov. 03, 2021 (GLOBE NEWSWIRE) — FOMO CORP. (https://www.fomoworldwide.com/ – US OTC: FOMC) is pleased to announce the following Advisory Board appointments that contribute substantial corporate, financial, and industry experience to the Company’s leadership team: John Conklin, Chief Executive & Operating Officer for the Energy Intelligence Center, LLC (https://energyintelligencecenter.com/) and IAQ Technologies, LLC (https://iaqtech.com/). Mr. Conklin has over 34 years of industrial, commercial, and renewable and alternative energy experience, has provided companies strategic management, operations, and governance expertise, and provided technical and business consulting services to more than fifty technology, manufacturing, and industrial process companies, and held executive positions as a CEO, CFO, and...

Berlin, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Calvin B. Taylor Bankshares, Inc. (the “Company”) (OTCQX: TYCB), parent company of Calvin B. Taylor Bank, today reported net income of $2.67 million for the third quarter ended September 30, 2021 (“3Q21”), as compared to $1.91 million for the third quarter ended September 30, 2020 (“3Q20”) and $2.07 million for the second quarter ended June 30, 2021 (“2Q21”).  Net income for the nine months ended September 30, 2021 was $7.34 million, as compared to $5.85 million for the nine months ended September 30, 2020.  Highlights of the company’s financial results are noted below and included in the following tables. Repayments of Paycheck Protection Program (“PPP”) loans by the Small Business Administration (“SBA”) associated with loan forgiveness was $20.6 million in...

Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma Experience PALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. Mr. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of “hands-on” biopharma experience. He is known as a consummate dealmaker with a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment...

IGE+XAO Société Anonyme with capital of 5,021,866.85 euros Head office : 16 Boulevard Déodat de Séverac 31770 COLOMIERS 338 514 987 RCS Toulouse SIRET: 338 514 987 000 76 – VAT number: FR 783.385.149.87     Regulated information   Statement regarding the total number of shares and voting rights composing the registered capital on 31 October 2021   In accordance with the article L.233-8 II of the French Commercial Code and with the article 223-16 of the French Financial Market Authority (AMF) General Rule.   Toulouse, on 3 November 2021   Total number of shares composing the registered capital: 1,304,381   Total number of voting rights: Gross (1): 2,256,580 Net (2): 2,252,146   (1) In conformity with the article 223-11 of the AMF General Rule, the total number of voting rights is calculated on the basis of the whole shares composing the...